2 weeks Ago By Defense World Staff
Shares of Boston Scientific Co. ( NYSE:BSX – Get Free Report ) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-three brokerages that are presently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company.
The average 12 month price target among brokerages that have issued a report on the stock in the last year is $93.39. BSX has been the topic of several recent analyst reports.
Sanford C. Bernstein raised their price objective on Boston Scientific from $92.00 to $100.
00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. Evercore ISI upped their target price on Boston Scientific from $82.00 to $90.
00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Truist Financial upped their price objective on Boston Scientific from $90.00 to $100.
00 and gave the company a “buy” rating in a research note on Monday, October 14th. Bank of America raised their price objective on shares of Boston Scientific from $90.00 to $100.
00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. Finally, BTIG Research boosted their target price on shares of Boston Scientific from $84.00 to $93.
00 and gave the company a “buy” rating in a research note on Monday, October 14th. Check Out Our Latest Research Report on BSX Insider Activity at Boston Scientific Institutional Trading of Boston Scientific A number of hedge funds and other institutional investors have recently modified their holdings of the business. CRA Financial Services LLC grew its holdings in Boston Scientific by 4.
3% in the third quarter. CRA Financial Services LLC now owns 2,841 shares of the medical equipment provider’s stock worth $238,000 after purchasing an additional 117 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its stake in shares of Boston Scientific by 9.
7% in the 3rd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 1,352 shares of the medical equipment provider’s stock worth $115,000 after buying an additional 119 shares during the last quarter. Adero Partners LLC increased its position in Boston Scientific by 3.
6% during the 3rd quarter. Adero Partners LLC now owns 3,617 shares of the medical equipment provider’s stock valued at $303,000 after buying an additional 127 shares in the last quarter. Ashton Thomas Securities LLC raised its stake in Boston Scientific by 1.
3% during the third quarter. Ashton Thomas Securities LLC now owns 9,968 shares of the medical equipment provider’s stock valued at $835,000 after buying an additional 129 shares during the last quarter. Finally, CVA Family Office LLC boosted its holdings in Boston Scientific by 7.
4% in the second quarter. CVA Family Office LLC now owns 1,909 shares of the medical equipment provider’s stock worth $147,000 after acquiring an additional 131 shares in the last quarter. 89.
07% of the stock is owned by hedge funds and other institutional investors. Boston Scientific Price Performance Boston Scientific stock opened at $90.00 on Friday.
The stock has a market capitalization of $132.64 billion, a price-to-earnings ratio of 74.38, a PEG ratio of 2.
69 and a beta of 0.79. Boston Scientific has a 52-week low of $53.
93 and a 52-week high of $91.93. The company has a debt-to-equity ratio of 0.
44, a quick ratio of 1.02 and a current ratio of 1.48.
The stock’s 50 day moving average price is $85.99 and its two-hundred day moving average price is $80.16.
Boston Scientific ( NYSE:BSX – Get Free Report ) last posted its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.
59 by $0.04. Boston Scientific had a net margin of 11.
26% and a return on equity of 17.23%. The business had revenue of $4.
21 billion during the quarter, compared to the consensus estimate of $4.04 billion. During the same quarter last year, the firm posted $0.
50 EPS. Boston Scientific’s revenue was up 19.3% compared to the same quarter last year.
On average, equities analysts predict that Boston Scientific will post 2.46 earnings per share for the current year. Boston Scientific Company Profile ( Get Free Report Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. Recommended Stories Five stocks we like better than Boston Scientific The Most Important Warren Buffett Stock for Investors: His Own Vertiv’s Cool Tech Makes Its Stock Red-Hot Are These Liquid Natural Gas Stocks Ready For An Upside Bounce? MarketBeat Week in Review – 11/18 – 11/22 What Are Dividend Challengers? 2 Finance Stocks With Competitive Advantages You Can’t Ignore Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.
com's FREE daily email newsletter ..
